Reading SLSN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SLSN free→Reading SLSN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SLSN free→NASDAQConsumer StaplesHousehold & Personal ProductsSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality is fragile, indicating that reported profits are not well supported by cash. Management's recent track record has been neutral, and the company has a capital-friendly stance. Risk is high, and the sector backdrop is a headwind, with SLSN trading below typical compared to its peers. Peer multiples imply a price about 277% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $1.26. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $1.26 SLSN trades at 2× p/s — 1.8× the 1× p/s peer median. The market is re-rating it beyond its own range; our $0.34 fair value is medium-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 273% near-term growth, well above our forecast of about -7%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality.
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Consumer Staples names rated weak grew net income 56% of the time over the next year (vs 58% for the rest of the cohort, n=1144).
Over the trailing year it converted 0.18x of net income into operating cash flow. Historically, Consumer Staples names rated fragile grew net income 51% of the time over the next year (vs 57% for the rest of the cohort, n=1037).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLP
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$492.
How much price usually moves either way.
On a bad day, this stock has moved -$938.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,444.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Retail sales give insight into consumer behavior. A strong report may boost Solesence's outlook.
Confirms one read:June retail sales increase by more than 0.5% month over month.
Confirms the other:June retail sales decrease by more than 0.5% month over month.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SLSN yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 12, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Household Products.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SLSN Solesence, Inc. | Below typical Show detailsSector percentile: 6 of 100 | expensive | high |
CL Colgate-Palmolive | Typical Show detailsSector percentile: 56 of 100 | full | moderate |
KMB Kimberly-Clark | Above typical Show detailsSector percentile: 91 of 100 | fair | moderate |
CHD Church & Dwight | Typical Show detailsSector percentile: 38 of 100 | expensive | low |
CLX Clorox | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
9 material management or governance events in the past 24 months, led by executive changes. Historically, Consumer Staples names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=491).
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to increase revenue to approximately $64 million for the year 2025.
Newly stated in 2025-Q4. Revenue grew from $12.5M in 2024-Q4 to $12.9M in 2026-Q1, indicating limited progress towards the $64M target for 2025. The trajectory shows a need for accelerated growth to meet the stated goal.
“we're projecting around $64 million for the year essentially, which would put us up roughly $12 million...”
Management is focused on improving operating income, which has fluctuated over recent quarters.
Newly stated in 2026-Q1. Operating income fell from $187,000 in 2025-Q4 to -$504,000 in 2026-Q1, indicating a decline in operational efficiency. The trajectory shows a need for significant improvement to achieve positive operating income.
“Operating income was -$504,000 in 2026-Q1, down from $187,000 in 2025-Q4.”
Why it matters: If revenue growth picks up, it could signal a positive shift for Solesence. This would counter the current cautious outlook.
Confirms:Reported revenue growth for Q2 2026 exceeds 4% year over year.
Disproves:Revenue growth for Q2 2026 is below 4% year over year.
Why it matters: FOMC decisions can change interest rates. This can affect Solesence's sales.
Confirms one read:FOMC raises rates, leading to a slowdown in consumer spending.
Confirms the other:FOMC keeps rates steady or lowers them, boosting consumer spending.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective April 24, 2026, the Board of Directors of the Company (the "Board") appointed Marc James to serve as a Class II Director of the Board for the remainder of the term of Class II Directors of the Board, expiring at the 2026 Annual Meeting of Shareholders of the Company. Mr. James has been appointed to the following committees of the Board: A…
Results of Operations and Financial Condition. On March 31, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. The Company previously reported on a Current Report on Form 8-K dated December 1, 2025 that former CEO, Jess Jankowski had resigned as an officer of the Company. Subsequently, the Company entered into a Separation Agreement and General Release of All Claims, effective as of December 2, 2025, with Mr. Jankowski (the "Separation Agreement"). Pursuant…
Entry into a Material Definitive Agreement. Effective November 22, 2025, Solesence, Inc. (the "Company") entered into a Consulting Agreement (the "Consulting Agreement") with Jess Jankowski. As previously disclosed, Mr. Jankowski, who formerly served as Chief Executive Officer and Chief Financial Officer of the Company, served as Board Advisor to the Company through his retirement on November 21, 2025. Pursuant to the Consulting Agreement, Mr. Jankowski will provide up to 80 hours of consulti…